- Home
- NUVL vs CRK Comparison
NUVL vs CRK Comparison
Compare NUVL & CRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CRK
- Stock Information
- Founded
- NUVL 2017
- CRK 1983
- Country
- NUVL United States
- CRK United States
- Employees
- NUVL N/A
- CRK N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CRK Oil & Gas Production
- Sector
- NUVL Health Care
- CRK Energy
- Exchange
- NUVL Nasdaq
- CRK Nasdaq
- Market Cap
- NUVL 5.6B
- CRK 5.8B
- IPO Year
- NUVL 2021
- CRK N/A
- Fundamental
- Price
- NUVL $75.00
- CRK $30.50
- Analyst Decision
- NUVL Strong Buy
- CRK Hold
- Analyst Count
- NUVL 8
- CRK 10
- Target Price
- NUVL $115.50
- CRK $21.67
- AVG Volume (30 Days)
- NUVL 452.9K
- CRK 2.1M
- Earning Date
- NUVL 08-07-2025
- CRK 07-30-2025
- Dividend Yield
- NUVL N/A
- CRK N/A
- EPS Growth
- NUVL N/A
- CRK N/A
- EPS
- NUVL N/A
- CRK N/A
- Revenue
- NUVL N/A
- CRK $1,431,537,000.00
- Revenue This Year
- NUVL N/A
- CRK $51.46
- Revenue Next Year
- NUVL N/A
- CRK $15.95
- P/E Ratio
- NUVL N/A
- CRK N/A
- Revenue Growth
- NUVL N/A
- CRK 1.43
- 52 Week Low
- NUVL $55.54
- CRK $7.74
- 52 Week High
- NUVL $113.51
- CRK $31.15
- Technical
- Relative Strength Index (RSI)
- NUVL 48.73
- CRK 81.55
- Support Level
- NUVL $76.42
- CRK $23.71
- Resistance Level
- NUVL $78.94
- CRK $24.73
- Average True Range (ATR)
- NUVL 2.71
- CRK 1.23
- MACD
- NUVL -0.34
- CRK 0.59
- Stochastic Oscillator
- NUVL 31.73
- CRK 91.79
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CRK Comstock Resources Inc.
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. Its oil and gas operations are concentrated in Louisiana and Texas.